|Articles|October 28, 2020
In vitro glycoengineering – Suitability for BioPharma manufacturing
Author(s)Roche
Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FAQ: What You Need to Know About Agentic AI in Drug Discovery
2
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5